Health Care • Medicinal Chemicals and Botanical Products
$6.86 ▼ -0.41
(-5.64%)
MKT CAP: $3.40B • VOL: 183.7K
52W L $5 52W H $69
ROARABLE / RQD
D- • 38/100
PIOTROSKI
2 / 9
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$6
MEDIAN
$8
MEAN
$8
HIGH
$9
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE RGC TAPE
RGC // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $8.30 | $7.89 | 2025-02-14 | $6.24 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $8.64 | $8.09 | 2025-02-06 | $6.45 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $7.82 | $7.55 | 2025-01-29 | $6.59 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $7.00 | — | 2025-01-17 | $6.72 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $6.04 | $6.52 | 2025-01-09 | $6.11 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $8.16 | $7.13 | 2024-12-18 | $5.97 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $6.65 | $6.93 | 2024-12-04 | $6.38 | -4.3% | 48% | C |